47 search results for: itch

The Role of IL-4 and IL-13 in CSU Pathogenesis
Type 2 Inflammation
The Role of IL-4 and IL-13 in CSU Pathogenesis
interactivity

Dive into the complex pathophysiology of chronic spontaneous urticaria (CSU), where mast cell degranulation drives the hallmark signs and symptoms. This interactive infographic elucidates how key type 2 cytokines, specifically IL-4 and IL-13, contribute to mast cell activation, immune cell trafficking into the skin, and neuronal sensitization in CSU, which ultimately leads to the release of mediators like histamine that cause wheals, angioedema, and itch.

View more
World Congress of Dermatology (WCD) 2023 | Singapore
Congress
4
July
2023
Congress
World Congress of Dermatology (WCD) 2023 | Singapore

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.

Sarina Elmariah
Expert
Sarina Elmariah, MD, PhD, MPH

Associate Professor and Dermatology Director at the UCSF Centre for Itch and Neurosensory Disorders at the University of California in San Francisco, California, US

A brief overview of the pathophysiology of PN
Dermatology
A brief overview of the pathophysiology of PN
expert video

Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.

View more
Describing Disease Control in PN
Dermatology
Describing Disease Control in PN
expert video

Dr. Chovatiya discusses PN, emphasizing that while itch is a major symptom, the disease's burden is multi-dimensional, affecting appearance, sleep, social life, and mental health, requiring comprehensive therapeutic solutions.

View more
Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU
Dermatology
Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU
expert video

Dr. Kim discusses the roles of type 2 cytokines at the neuroimmune axis in PN and CSU and conveys how neuroimmune interactions give rise to chronic itch and skin lesions in each disease

View more
Type 2 Inflammation Within Skin Tissue in AD
Dermatology
Type 2 Inflammation Within Skin Tissue in AD
expert video

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to epidermal barrier dysfunction, perivascular infiltration and plasma protein leakage, and chronic itch in AD.

View more
In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves
Type 2 Inflammation
In Chronic Pruritic Skin Diseases, the Neuroimmune Axis Involves Dynamic Interactions Between Type 2 Inflammation and Sensory Nerves
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Brian Kim describes the dynamic neuroimmune interactions in chronic pruritic skin diseases, emphasizing how type 2 cytokines and sensory nerves actively influence both itch perception and tissue inflammation.

View more
CLCI in Atopic Dermatitis Infographic
Dermatology
CLCI in Atopic Dermatitis Infographic
Infographic

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

View more
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia
Congress
3
May
2024
Congress
European Society for Pediatric Dermatology (ESPD) 2024 | Košice, Slovakia

Inflammatory processes drive AD both within and beyond the skin, leading to significant, cumulative life impacts. Early intervention has the potential to mitigate these impacts by altering the disease course.